Muhammad Khan, MD
Pulmonary Disease · Toms River, NJNPI 1528253408
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AstraZeneca at 37.4% of the total. Reporting peaked in 2019 at $55 and has fallen 56.3% since, to $24 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NJ, where the typical reported total is $2,135.
Across 8 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$47
- Mylan Specialty L.p.$40
- Inspire Medical Systems, Inc.$24
- GSK$14
Across 1 payment — averaging $15,255 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$15K
What the payments were for
- Food & beverage$125100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $47 |
| Mylan Specialty L.p. | 3 | $40 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| GSK | 1 | $14 |
How this compares
$125 in reported general payments places this provider in the 10th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 244 | $177,717 |
| Breo ElliptaFluticasone/Vilanterol | 221 | $121,063 |
| Spiriva RespimatTiotropium Bromide | 75 | $57,851 |
| Incruse ElliptaUmeclidinium Bromide | 86 | $34,970 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $24,538 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 150 | $18,473 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $15,253 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 55 | $12,909 |
| Tiotropium Bromide | 19 | $11,000 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 288 | $8,759 |
| Wixela InhubFluticasone Propion/Salmeterol | 49 | $6,979 |
| Advair DiskusFluticasone Propion/Salmeterol | 26 | $5,322 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,276 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,095 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 14 | $4,974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $14 | $352,850596 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $47 | $34,42962 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Toms River
- Vinay SikandToms River$96K
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.